This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / HKSTP CTC Marketplace Showcases...
Business Biotech Showcase

HKSTP CTC Marketplace Showcases Biotech Success

Analysis based on 8 articles · First reported Mar 18, 2026 · Last updated Mar 18, 2026

Sentiment
60
Attention
4
Articles
8
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The event highlights Hong Kong's growing importance as a biotech hub, attracting investment and facilitating commercialisation for companies like Health Hope Pharma, Arthrosi Therapeutics, Nuance Pharma, and InxMed. This positive development is expected to boost investor confidence in the region's life and health tech sector.

Biotechnology Pharmaceuticals Venture Capital
Event Summary

The Hong Kong===Hong Kong Science and Technology Parks Corporation (HKSTP) hosted the CTC Marketplace Showcase Event on March 18, 2026, to accelerate Hong Kong's life and health tech sector. The event brought together 110 industry pioneers, investors, and corporate partners to discuss biotech success, Hong Kong's policy advantages, and its emergence as a global clinical trial hub. HKSTP, with over 300 life and health tech companies in its ecosystem, aims to bridge the gap from lab discovery to global market access. Key companies like Health Hope Pharma, Arthrosi Therapeutics, Nuance Pharma, and InxMed shared their milestones, including licensing deals, significant funding rounds, acquisitions, and IPO applications, demonstrating the ecosystem's success.

Key Actions
100 Hong Kong===Hong Kong Science and Technology Parks Corporation hosted CTC Marketplace Showcase Event
90 Arthrosi Therapeutics was acquired
85 Health Hope Pharma secured licensing agreement Gilead Sciences
80 Arthrosi Therapeutics achieved Series E funding
75 Nuance Pharma leveraged '1+' mechanism for commercialisation
70 Hong Kong===Department of Health (Hong Kong) approved Ohtuvayre™ Nuance Pharma
70 InxMed submitted IPO application Hong Kong Stock Exchange
60 InxMed completed five rounds of financing
Entities Involved
govactor
Hong Kong===Hong Kong Science and Technology Parks Corporation
Hong Kong===Hong Kong Science and Technology Parks Corporation (HKSTP) hosted the CTC Marketplace Showcase Event, demonstrating its commitment to accelerating Hong Kong's life and health tech sector. HKSTP's ecosystem supports over 300 life and health tech companies, providing infrastructure, funding, and regulatory guidance to bridge the gap from lab discovery to global market access.
Importance 100 Sentiment 70
loc
Hong Kong
Hong Kong is positioned as a global clinical trial hub and a key location for life and health tech innovation, supported by the Hong Kong===Hong Kong Science and Technology Parks Corporation and government policies.
Importance 90 Sentiment 50
priv
Health Hope Pharma
Health Hope Pharma, a Hong Kong-headquartered late-stage clinical oncology biopharma, secured a major licensing agreement with Gilead Sciences, potentially valued at up to USD 82.5 million. This agreement highlights the company's success in developing novel oral anti-cancer drugs.
Importance 80 Sentiment 75
priv
Arthrosi Therapeutics
Arthrosi Therapeutics Inc., a US-based clinical-stage biotechnology company, achieved USD 153 million in Series E funding and a subsequent acquisition valued at USD 1.5 billion. This success underscores the company's progress in developing treatments for gout.
Importance 80 Sentiment 85
priv
Nuance Pharma
Nuance Pharma leveraged the '1+' mechanism to expedite commercialisation in Hong Kong, with the Department of Health approving Ohtuvayre™ in March 2026. This marks the first drug targeting chronic obstructive pulmonary disease to gain approval under this scheme.
Importance 75 Sentiment 70
priv
InxMed
InxMed (Hong Kong) Limited submitted its IPO application to the Hong Kong Stock Exchange in August 2025, having completed five rounds of financing totaling over USD 130 million. The company focuses on addressing drug resistance in cancer therapy.
Importance 70 Sentiment 65
stock
Gilead Sciences
Gilead Sciences entered into a major licensing agreement with Health Hope Pharma, potentially valued at up to USD 82.5 million. This deal expands Gilead Sciences' portfolio in oncology.
Importance 60 Sentiment 20
+ 7 more entities View on Dashboard
Relationships
Terry Wong related ↔ Hong Kong===Hong Kong Science and Technology Parks Corporation
Dennis Lam related ↔ Health Hope Pharma
Shunqi Yan related ↔ Arthrosi Therapeutics
Charlie Chen related ↔ Nuance Pharma
Francis Cao related ↔ InxMed
Hong Kong===Hong Kong Science and Technology Parks Corporation related ↔ Health Hope Pharma
Hong Kong===Hong Kong Science and Technology Parks Corporation related ↔ Arthrosi Therapeutics
Hong Kong===Hong Kong Science and Technology Parks Corporation related ↔ Nuance Pharma
Hong Kong===Hong Kong Science and Technology Parks Corporation related ↔ InxMed
Health Hope Pharma related ↔ Arthrosi Therapeutics
+ 5 more relationships View on Dashboard
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.